Apellis Pharmaceuticals, Inc. (APLS) Reports Q4 Earnings: What Key Metrics Have to Say
APLSApellis(APLS) Zacks Investment Research·2024-02-27 23:36

Apellis Pharmaceuticals, Inc. (APLS) reported 146.38millioninrevenueforthequarterendedDecember2023,representingayear−over−yearincreaseof546146.38 million in revenue for the quarter ended December 2023, representing a year-over-year increase of 546%. EPS of -0.73 for the same period compares to -1.50ayearago.ThereportedrevenuecomparestotheZacksConsensusEstimateof1.50 a year ago. The reported revenue compares to the Zacks Consensus Estimate of 146.43 million, representing a surprise of -0.03%. The company delivered an EPS surprise of -10.61%, with the consensus EPS estimate being -$0.66. While investors closely watch year-over-year changes in headline numbers -- ...